Abstract
Introduction: This study aims to establish the mortality rates of pulmonary hypertension (PH) patients treated at the Ege University Hospital PH Centre and to demonstrate the variation of mortality by aetiology.
Methods: The study retrospectively and prospectively examined 167 adult PH patients undergoing right heart catheterisation between January 2008 and October 2014, reviewed and treated by a multidisciplinary team.
Results: By Nice PH Classification, 115 of the patients were Group 1-PAH, 14 Group 3-ILD and 38 Group 4-CTEPH. Within Group 1, 33 (19.5%) were IPAH, 69 (40.8%) were CHD-APAH and 13 (7.7%) were CTD-APAH. Sixty-three patients (37.7% of the study group) have not survived the observation period. 85.7% of the ILD-PH group have died, compared to 27.5% of the CHD-APAH group. Taking group 1 IPAH group as a reference, the mortality risk of the CHD-APAH group was relatively low (HR=-0.40); however the risk was 4.54 times higher for the patients with ILD-PH (group 3). A significant difference has not been observed for other groups. As the WHO-FC category increased, risk increased by 3 to 4 times in comparison to WHO-FC II. One unit increase in cardiac index or DLCO (percent predicted) reduces the risk (HR=0.57, HR=0.97 respectively). BNP value higher than 150pg/mL and NT-proBNP value higher than 553pg/mL are determining factors for mortality (p=0.018, p=0.001 respectively).
Conclusion: This study indicates that PH patient profiles and survival are different from European and American examples, CHD-APAH being the most prevalent patient population with better survival.
- Copyright ©ERS 2015